Research Peptides · Cat. 019-16
Corticotropin Releasing Factor (CRF) (9-41), alpha-helical (Ovine)
Supplied as 200 µg per unit. Purity ≥ 95%. Molecular weight 3826.43. Species: Ovine. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | 019-16 |
|---|---|
| Product type | Research Peptides |
| Peptide family | Corticotropin & CRF Peptides |
| Species | Ovine |
| Unit size | 200 µg |
| Molecular weight | 3826.43 Da |
| Purity | ≥ 95% |
| Validation | Exhibits correct molecular weight |
| Appearance | White powder |
| Contents | Each vial contains 200 µg of NET peptide. In vivo administration of corticotropin-releasing hormone at remote intervals following ischemia enhances CA1 neuronal survival and recovery of spatial memory impairments: a role for opioid receptors. Charron C, Fréchette S, Proulx G, Plamondon H. Behav Brain Res. 2008;188(1):125-35. Effects of in vivo and in vitro administration of ghrelin, leptin and neuropeptide mediators on pulsatile gonadotrophin-releasing hormone secretion from male rat hypothalamus before and after puberty. Lebrethon MC, Aganina A, Fournier M, Gérard A, Parent AS, Bourguignon JP. J Neuroendocrinol. 2007;19(3):181-8. Corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 are both trafficking and signaling receptors for urocortin. Tu H, Kastin AJ, Pan W. Mol Endocrinol. 2007;21(3):700-11. The CRH1 antagonist CP154,526 failed to alter ischemia-induced neurodegeneration and spatial memory deficits in rats but inhibited behavioral activity in the novel open field. Plamondon H, Khan S. Behav Brain Res. 2006;166(1):85-92. Prolactin-releasing peptide and its homolog RFRP-1 act in hypothalamus but not in anterior pituitary gland to stimulate stress hormone secretion. Samson WK, Keown C, Samson CK, et al. Endocrine. 2003;20(1-2):59-66. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Correia ML, Morgan DA, Mitchell JL, Sivitz WI, Mark AL, Haynes WG. Hypertension. 2001;38(3):384-8. Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. Leitch IM, Boura AL, Botti C, Read MA, Walters WA, Smith R. J Clin Endocrinol Metab. 1998;83(12):4510-3. |
| Solubility | Insoluble in water. Dissolve in 100-500 µl of 0.1M ammonium hydroxide or any other basic buffer ( pH > 9). |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Sequence
Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2
Storage & handling
Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
Confirm handling and preparation requirements against current product documentation and the requirements of your laboratory protocol.
Frequently asked
What is Corticotropin Releasing Factor (CRF) (9-41), alpha-helical (Ovine)?
What purity is listed for 019-16?
How should Corticotropin Releasing Factor (CRF) (9-41), alpha-helical (Ovine) be stored?
What is the sequence of Corticotropin Releasing Factor (CRF) (9-41), alpha-helical (Ovine)?
What is the intended use of 019-16?
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.